HCPCS J3404: Injection of Zopapogene Imadenovec-Drba Suspension, Therapeutic Dose

HCPCS Level II code J3404 denotes an injected dose of zopapogene imadenovec-drba suspension, a gene therapy product delivered as a therapeutic injectable. As a product-specific HCPCS J-code, J3404 is used on medical claims to identify the drug administered and to support payment and utilization tracking across outpatient infusion centers and hospital outpatient departments.

This national overview discusses reimbursement and coverage patterns for major payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the code's clinical context, the typical sites of care where the drug is administered, and the claim-level role of a J-code for high-cost specialty biologics and gene therapies.

The publication summarizes key benchmarks and policy considerations relevant to J3404, including how payers may handle prior authorization, medical benefit billing, and site-of-service considerations for infused gene therapies. It also outlines the types of analytical benchmarks and administrative updates payers and providers commonly monitor — such as unit billing conventions, dosage-per-claim implications, and the interaction with medical benefit coverage policies. Data not available in the input will be noted where applicable.

Billing Code Overview

HCPCS Level II code J3404 represents an injection of zopapogene imadenovec-drba suspension, per therapeutic dose. This medication is a gene therapy administered as an injectable pharmaceutical product intended to deliver a therapeutic dose of the suspended viral vector.

Service type: Injectable gene therapy medication
Typical site of service: Infusion center or hospital outpatient setting

Data not available in the input.

Clinical Context

A typical patient is an adult with a rare genetic retinal dystrophy or other inherited ocular disorder qualifying for gene therapy with J3404 (zopapogene imadenovec-drba). The patient presents to an ophthalmology ambulatory surgical center or hospital outpatient department for intravitreal or subretinal administration of the gene therapy suspension per the product's dosing instructions. Pre-procedure workflow includes informed consent, review of prior ophthalmic imaging (OCT, fundus photography), baseline visual acuity and intraocular pressure measurements, and preoperative anesthesia assessment. On the day of service the patient receives regional or monitored anesthesia care; the ophthalmic surgeon prepares and administers the J3404 therapeutic dose via the appropriate surgical approach (commonly subretinal injection during a pars plana vitrectomy). Post-procedure care includes immediate recovery monitoring for intraocular pressure, inflammation, and retinal status, discharge instructions, and scheduled follow-up visits with ocular exam and imaging. Typical sites of service are an ambulatory surgical center (ASC), hospital outpatient department (HOPD), or specialized ophthalmic surgical suite where sterile intraocular gene therapy delivery is performed.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component

Taxonomy Code	Specialty	Notes
`207SX0100X`	Ophthalmology	Surgeon administering intraocular gene therapy
`2080P0207X`	Retina/Vitreous Specialist	Subspecialist performing vitrectomy and subretinal injection
`363L00000X`	Anesthesiology	Provides monitored anesthesia care or regional/general anesthesia
`251S00000X`	Clinical Geneticist	May be involved in genetic diagnosis and eligibility evaluation
`261QM0800X`	Nurse Practitioner	Perioperative and follow-up care under supervising physician

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`H35.52`	Hereditary retinal dystrophy, bilateral	Represents inherited retinal disorders that may be indications for ocular gene therapy
`H35.53`	Hereditary retinal dystrophy, right eye	Indicates unilateral involvement when therapy targets the right eye
`H35.54`	Hereditary retinal dystrophy, left eye	Indicates unilateral involvement when therapy targets the left eye
`H35.8`	Other retinal disorders	Captures atypical retinal pathology that may qualify for investigational or approved gene therapy
`Z15.01`	Genetic susceptibility to eye disease	Used when genetic testing identifies susceptibility or pathogenic variant guiding therapy

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`67108`	Repair of retinal detachment; complex (vitrectomy, with or without other procedures)	May be used when pars plana vitrectomy is required to access the subretinal space for gene therapy delivery
`67036`	Vitrectomy, mechanical, pars plana approach; with removal of vitreous opacities and/or membrane peeling	Commonly performed as part of surgical approach to permit safe subretinal injection
`67028`	Intravitreal injection of a pharmacologic agent (eg, anti-VEGF)	Describes intravitreal injection technique; CPT used when intravitreal route is used instead of subretinal
`66210`	Repair of retinal detachment via scleral buckle; without vitrectomy	May be relevant if combined vitreoretinal procedures are required
`99070`	Supplies and materials (eg, sutures, sterile gowns), used during the procedure, billed separately	Used to report additional non-physician-supplied supplies during the operative encounter

OpenPayer

Summary & Overview